RxDoctor Payments Data

Michael Jansen, MD

Clinical Cardiac Electrophysiology · Gainesville, FLNPI 1740302587

Payments from drug & device makers

$27,359in general payments, 2019–2025

Across 232 payments — averaging $117.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$20K
  • Elutia, Inc.$3K
  • Biosense Webster, Inc.$2K
  • Medtronic$731
  • Pfizer$291
  • Novartis$231
  • plus $1K from 21 others

What the payments were for

  • Consulting fees$400%
  • Speaking & faculty fees$21,05077%
  • Travel & lodging$1,0834%
  • Food & beverage$5,17619%
  • Gifts$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,359 in reported general payments places this provider in the 40th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,296,221
Medicare patients
2,312
Services billed
9,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban659$677,982
EntrestoSacubitril/Valsartan144$135,271
XareltoRivaroxaban170$134,472
JardianceEmpagliflozin111$84,767
FarxigaDapagliflozin Propanediol54$47,828
Repatha SureclickEvolocumab44$31,552
MultaqDronedarone Hcl13$19,722
CorlanorIvabradine Hcl13$9,619
Dofetilide28$8,455
Flecainide Acetate227$7,281
Dabigatran EtexilateDabigatran Etexilate Mesylate24$6,687
Diltiazem 24hr Er (Cd)Diltiazem Hcl201$6,047
Metoprolol Succinate444$5,686
Atorvastatin Calcium331$2,942
SotalolSotalol Hcl163$2,685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$291$677,982659 claims
NovartisEntresto$231$135,271144 claims
Johnson & JohnsonXarelto$81$134,472170 claims
AstraZenecaFarxiga$19$47,82854 claims
Sanofi-aventis U.S. LLCMultaq$20$19,72213 claims
AmgenCorlanor$184$9,61913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →